Troriluzole

Add links
Source: Wikipedia, the free encyclopedia.
Troriluzole
Clinical data
Other namesTrigriluzole, BHV-4157, FC-4157
Routes of
administration		By mouth
Identifiers
  • 2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide
JSmol)
  • CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN
  • InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17)18/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25)
  • Key:YBZSGIWIPOUSHY-UHFFFAOYSA-N

Troriluzole (trigriluzole) is an experimental medication that has been investigated as a potential treatment for

obsessive-compulsive disorder,[3][4] and glioblastoma.[5] It is a prodrug formulation of the medication riluzole.[3][5]

Pharmacology

Pharmacokinetics

While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.[3][5]

References

  1. ^ Meglio, Marco (25 June 2023). "Biohaven Submits New Drug Application for Troriluzole as Spinocerebellar Ataxia Type 3 Therapy". NeurologyLive. Retrieved 17 February 2024.
  2. ^ Waldron, James (27 July 2023). "Further blow for Biohaven as FDA refuses to consider failed rare disease drug for approval". Fierce Biotech. Retrieved 17 February 2024.
  3. ^
    PMID 33447096
    .
  4. ^
    PMID 36368186
    .
  5. ^
    PMID 35780243
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Troriluzole&oldid=1210341711"